Department of Histology, Medical University of Gdansk, 1a Debinki, 80-211 Gdansk, Poland.
School of Molecular Sciences, University of Western Australia, Perth, WA 6009, Australia.
Int J Mol Sci. 2024 Oct 10;25(20):10914. doi: 10.3390/ijms252010914.
Despite the recent development of improved methods of treating melanoma such as targeted therapy, immunotherapy or combined treatment, the number of new cases worldwide is increasing. It is well known that active metabolites of vitamin D and lumisterol (L) exert photoprotective and antiproliferative effects on the skin, while UV radiation is a major environmental risk factor for melanoma. Thus, many natural metabolites and synthetic analogs of steroidal and secosteroidal molecules have been tested on various cancer cells and in animal models. In this study, we tested the anti-melanoma properties of several natural derivatives of vitamin D and L in comparison to 1,25-dihydroxyvitamin D (1,25(OH)D). A significant decrease in melanoma cell proliferation and cell mobility was observed for selected derivatives, with (25R)-27-hydroxyL showing the highest potency (lowest IC50) in A375 cells but lower potency in SK-MEL-28 cells, whereas the parent L failed to inhibit proliferation. The efficacy (% inhibition) by 1,24,25(OH)D and 1,25(OH)D were similar in both cell types. 1,25(OH)D showed higher potency than 1,24,25(OH)D in SK-MEL-28 cells, but lower potency in A375 cells for the inhibition of proliferation. As for 1,25(OH)D, but not the other derivatives tested, treatment of melanoma cells with 1,24,25(OH)D markedly increased the expression of CYP24A1, enhanced translocation of the vitamin D receptor (VDR) from the cytoplasm to the nucleus and also decreased the expression of the proliferation marker Ki67. The effects of the other compounds tested were weaker and occurred only under certain conditions. Our data indicate that 1,24,25(OH)D, which has undergone the first step in 1,25(OH)D inactivation by being hydroxylated at C24, still shows anti-melanoma properties, displaying higher potency than 1,25(OH)D in SK-MEL-28 cells. Furthermore, hydroxylation increases the potency of some of the lumisterol hydroxy-derivatives, as in contrast to L, (25)-27(OH)L effectively inhibits proliferation and migration of the human malignant melanoma cell line A375.
尽管最近开发了一些治疗黑色素瘤的改良方法,如靶向治疗、免疫疗法或联合治疗,但全球新发病例数量仍在增加。众所周知,维生素 D 的活性代谢物和 lumisterol(L)对皮肤具有光保护和抗增殖作用,而紫外线辐射是黑色素瘤的主要环境危险因素。因此,许多天然代谢物和甾体和 secosteroidal 分子的合成类似物已在各种癌细胞和动物模型中进行了测试。在这项研究中,我们测试了几种维生素 D 和 L 的天然衍生物在比较 1,25-二羟基维生素 D(1,25(OH)D)时的抗黑色素瘤特性。我们观察到,选定的衍生物可显著降低黑色素瘤细胞的增殖和细胞迁移,其中(25R)-27-羟基 L 在 A375 细胞中显示出最高的效力(最低 IC50),但在 SK-MEL-28 细胞中的效力较低,而母体 L 未能抑制增殖。在这两种细胞类型中,1,24,25(OH)D 和 1,25(OH)D 的疗效(%抑制)相似。1,25(OH)D 在 SK-MEL-28 细胞中的效力高于 1,24,25(OH)D,但在 A375 细胞中的效力较低,可抑制增殖。与 1,25(OH)D 一样,测试的其他衍生物不会增加 CYP24A1 的表达,增强维生素 D 受体(VDR)从细胞质到细胞核的易位,也不会降低增殖标志物 Ki67 的表达。其他测试化合物的作用较弱,仅在某些条件下发生。我们的数据表明,1,24,25(OH)D 已经在 C24 位发生了 1,25(OH)D 失活的第一步,仍然具有抗黑色素瘤特性,在 SK-MEL-28 细胞中显示出比 1,25(OH)D 更高的效力。此外,羟化作用增加了一些 lumisterol 羟基衍生物的效力,与 L 不同,(25)-27(OH)L 可有效抑制人恶性黑色素瘤细胞系 A375 的增殖和迁移。